Early lipid lowering critical in secondary prevention: study
Cardiologist says new evidence is ‘incredibly encouraging’
This content has been independently produced by ADG, made possible through sponsorship from Amgen
The results of a US study that show rapid LDL-C lowering within one day in patients who were given the PCSK9 inhibitor, evolocumab shortly after a heart attack “may reframe what we are able to do with our patients”, according to an Australian cardiologist.
